The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

On completion of docetaxel chemotherapy, patients at the Rosemere Cancer Centre (Preston, UK) are closely monitored every 4–6 weeks ... the potential to extend survival, but there is no evidence ...

A Comprehensive Review of Epidemiology, Risk Factors, and Treatment Strategies. Advances in Breast Cancer Research, 14, 1-15. doi: 10.4236/abcr.2025.141001 . Noncommunicable diseases like various ...

We expect the series to become a window through which more foreign readers will understand how Chinese people recognize human ...

Background Acute kidney injury (AKI) in the context of acute decompensated heart failure (ADHF) encompasses a broad spectrum ...

Among the poorest in Punjab and Sindh provinces, they are also victims of repeat floods caused by climate change ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.

A first person account of what it feels like to be a survivor of famine and ongoing acute food insecurity, by 20-year-old ...